

















1316Reduced Late Mortality Risk Contributes to Similar
Survival after Double-Unit Cord Blood Transplantation
Compared with Related and Unrelated Donor
Hematopoietic Stem Cell Transplantation
Doris M. Ponce,1,4 Junting Zheng,3 Anne Marie Gonzales,1 Marissa Lubin,1 Glenn Heller,3
Hugo Castro-Malaspina,1,4 Sergio Giralt,1 Katharine Hsu,1,4 Ann A. Jakubowski,1,4
Robert R. Jenq,1,4 Guenther Koehne,1,4 Esperanza B. Papadopoulos,1,4
Miguel A. Perales,1,4 Marcel R. van den Brink,1,4 James W. Young,1,4 Farid Boulad,2,4
Nancy A. Kernan,2 Rachel Kobos,2 Susan Prockop,2 Andromachi Scaradavou,2
Trudy Small,2,4 Richard J. O’Reilly,2,4 Juliet N. Barker1,4Cord blood transplantation (CB-T) is increasingly used as a treatment alternative for hematologic malignan-
cies. However, how CB-T compares to related (RD-T) and unrelated donor transplantation (URD-T) is not
established. We compared survival of 75 double-unit CB-T, 108 RD-T, and 184 URD-T recipients who re-
ceived transplants over the same period for the treatment of hematologic malignancies. Patients had similar
ages and disease risk, and a similar percentage had acute leukemia. The incidence of day 180 transplant-
related mortality (TRM) of 21% (95% confidence interval [CI]: 12-31) after CB-Twas higher than that of
RD-T recipients. However, this was compensated for by a low risk of TRM after day 180, and a relatively
low incidence of relapse. Hence, the 2-year progression-free survival (PFS) of 55% (95% CI: 45-68) after
CB-Twas similar to that after RD-Tor URD-T (P 5 .573). In multivariate analysis, donor source had no in-
fluence on PFS, with the only significant factors being recipient age and disease risk. In a subanalysis of 201
patients with acute leukemia, CB-T, RD-T, and URD-Trecipients also had similar 2-year disease-free survival
(P 5 .482). These data provide strong support for the further investigation of double-unit CB grafts as an
alternative hematopoietic stem cell source.
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6/j.bbmt.2011.01.006hematologic malignancies [1-4], and can extend
hematopoietic stem cell (HSC) transplant access to
racial and ethnic minorities [5]. In recent years, use
of CB as an alternative HSC source has increased
substantially [6]. Retrospective studies have been
conducted analyzing outcomes after single-unit CB-
T and traditional HSC sources. Compared with 8/8
human leukocyte antigen (HLA)-matched unrelated
donor (URD) bone marrow (BM) transplantation,
Eapen et al. [2] reported a similar 5-year disease-free
survival after 4-5/6HLA-matched CB-T, and superior
survival after 6/6 HLA-matched CB-T, in children.
Rocha et al. [7] found that single-unit CB-T had sim-
ilar outcomes to adult 6/6 HLA-matched URD BM
transplantation recipients. Laughlin et al. [8]
reported a similar leukemia-free survival after single-
unit myeloablative CB-T in adults compared to 5/6
HLA-matched URD BM transplantation, whereas
more recently, Eapen et al. [9] have found comparable
disease-free survival (DFS) after single-unit CB-T and
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plantation in adults. Despite these findings, CB-T
has not yet been widely adopted, likely because of
the risk of delayed or failed engraftment after single-
unit CB-T. We have observed, however, a high inci-
dence of sustained donor engraftment and promising
progression-free survival (PFS) after double-unit
CB-T [10]. Therefore, we conducted a retrospective
analysis of survival after related donor transplantation
(RD-T), URD transplantation (URD-T), and double-
unit CB-T performed at Memorial Sloan-Kettering
Cancer Center (MSKCC) over the same period for
the treatment of hematologic malignancies. Our hy-
pothesis was that the 2-year PFS is similar after trans-
plantation of the 3 HSC sources.PATIENTS AND METHODS
Patients and Graft Characteristics
This retrospective analysis was conducted on pa-
tients who underwentHSC transplantation atMSKCC
betweenOctober 1, 2005, and June30, 2009.Collection
and analysis of patient demographics and transplant
outcomes was approved by the Human Subject Institu-
tional Review Board. Eligible patients included adult
and pediatric recipients of first allograft for the treat-
ment of hematologic malignancies. For adult donors,
HLA-match was assessed at 10 HLA-alleles with ade-
quate donor-recipient HLA-match being 9-10/10
HLA-A, -B, -C, -DRB1, -DQ matched for RDs, 8-10/
10 HLA-matched for T cell–depleted URDs, and 9-
10/10 for an unmodifiedURDs.AllCB-T recipients re-
ceiveddouble-unit grafts.Unitswere selected according
to 4-6/6HLA-A, -B antigen, -DRB1 allele match to the
recipient, the cryopreserved total nucleated cell (TNC)
dose (at least 1.5 107/kg/unit), and the bank of origin
[10,11]. Unit-unit HLA-match was not considered in
CB unit selection. High-resolution typing of CB units
was done routinely but usually did not influence unit se-
lection.URDshadpriority as theHSCsource if patients
didnot have a suitableHLA-matched related donor;CB
was chosen if no suitably HLA-matched URDs were
available within the required time period.
Eligible diagnoses for this analysis included all con-
secutively transplanted patients with acute leukemia in
complete remission (CR1-3), myelodysplasia (MDS)
with #5% blasts, chronic myelogenous leukemia
(CML) in chronicoracceleratedphase, chronic lympho-
cytic leukemia (CLL), non-Hodgkin andHodgkin lym-
phoma, and multiple myeloma (MM). Patients with
refractory or relapsed acute leukemia, juvenile myelo-
monocytic leukemia, myeloproliferative disorders other
thanCML, and nonmalignant diseases were excluded as
were recipients of syngeneic transplants, second allo-
grafts, 2 prior autologous transplants, and \9/10
HLA-matched RD, or\8/10 HLA-matched URD.Conditioning Regimens and GVHD Prophylaxis
All patients were cared for in high-efficiency partic-
ulate air–filtered rooms and received similar supportive
care. Pretransplant conditioning varied according to
patient’s age, diagnosis, remission status, extent of prior
therapies, and comorbidities and consisted of high-
dose, reduced-intensitymyeloablative, andnonmyeloa-
blative regimens (Table 1). Graft-versus-host disease
(GVHD)prophylaxis forRD-TandURD-Trecipients
was either with T cell depletion [12] or calcineurin-
inhibitor (CNI) based. By contrast, all CB-T recipients
receivedCNI (predominantly cyclosporine-A) andmy-
cophenolate mofetil (1 g every 12 hours or 15 mg/kg if
\50 kg every 12 hours intravenously), and posttrans-
plant granulocyte colony-stimulating factor (G-CSF),
and none had anti-thymocyte globulin (ATG) [10]. G-
CSFwasused innon–CB-Trecipients according topro-
tocol or physician preference.Study Definitions
Standard-risk disease for acute myelogenous leuke-
mia (AML) or acute lymphoblastic leukemia (ALL)
was defined as first complete remission (CR1) without
high-risk cytogenetics or high-riskmolecular abnormal-
ities [13,14], de novo MDS with an International
Prognostic Scoring System score \2, CML in first
chronic phase, and chemotherapy-sensitive lymphoma
in less than second relapse for aggressive histologies or
less than third relapse for indolent disease without
prior autologous transplantation. All remaining
patients were considered high risk.
Patients were evaluable for engraftment from day
14 posttransplant. Neutrophil and platelet recovery
were defined as previously described [10]. Donor chi-
merism was determined serially on BM and blood after
transplantation. Primary graft failure was the lack of
donor-derived neutrophil recovery by day 45, or re-
quirement for either a boost from the same donor or
a second transplant for lack of count recovery. Second-
ary graft failure was defined as a fall in absolute
neutrophil count (ANC) to \0.5  109/L for $14
consecutive days after donor-derived neutrophil re-
covery, or requirement for a stem cell boost from the
same donor, a second transplant, or the use of ATG
as therapy for severe cytopenias that developed after
initial engraftment. Sustained donor engraftment was
defined as sustained donor-derived neutrophil recov-
ery, and included all patients without graft failure
and patients with graft failure who spontaneously re-
covered or were successfully rescued.
Acute and late acute/chronic GVHD (aGVHD,
cGVHD) were diagnosed clinically with histological
confirmation when possible. Staging of aGVHD was
based on International BM Transplant Registry crite-
ria [15]. Late aGVHD (including persistent aGVHD
after day 100 requiring ongoing therapy, or GVHD
Table 1. Patient Demographics and Graft Characteristics: Although a Similar Percentage of the Three Groups Had Acute Leu-
kemia, CB-T RecipientsWere More Likely to Have L:ymphoid Malignancies, a Prior Autologous Transplant, and Nonmyeloablative
Conditioning, and Receive Grafts That Were Considerably More HLA-Mismatched and with a Lower Cell Dose.
RD (n 5 108) URD (n 5 184) CB (n 5 75) P Value
Median age (range) 47 (<1-71) 48 (1-71) 37 (<1-66) .071
n (%) age >21 years 90 (83%) 145 (79%) 60 (80%) .634
n (%) male 60 (56%) 111 (60%) 42 (56%) .679
Median weight kg (range) 74 (9-122) 74 (8-139) 68 (7-109) .083
n (%) recipient CMV seropositive 53 (49%) 82 (45%) 43 (57%) .233
n (%) prior autologous transplant 6 (6%) 26 (14%) 14 (19%) .014
n (%) graft source
PBSC 98 (91%) 171 (93%)
BM 10 (9%) 13 (7%) — Not done
n (%) diagnosis
Acute leukemia 64 (59%) 99 (54%) 39 (52%) .054
AML/biphenotypic 43 66 24
ALL 21 33 15
MDS/CML 12 (11%) 27 (15%) 3 (4%)
Lymphoid malignancies* 32 (30%) 58 (32%) 33 (44%)
n (%) disease risk .207
Standard 21 (19%) 24 (13%) 8 (11%)
High 87 (81%) 160 (87%) 67 (89%)
n (%) myeloablative conditioning
(High dose and reduced intensity)
TBI-based† 46 (43%) 65 (35%) 43 (57%) .034
Chemotherapy-based‡ 43 (40%) 91 (49%) 10 (13%)
n (%) nonmyeloablative conditioning
TBI-based (200 cGy) 19 (17%) 27 (15%) 22 (29%)
Chemotherapy-based — 1 (<1%) —
n (%) GVHD prophylaxis
T cell depletion 71 (66%) 125 (68%) — <.001
CNI ± other 37 (34%) 59 (32%) 75 (100%)
Median donor-recipient HLA-A, -B, -C,
-DRB1, -DQ match (range)
10/10 (9-10/10) 10/10 (8-10/10) 6/10 (2-9/10) <.001
HLA-match grade 10/10 (106) 10/10 (110) 6/6 (5)§ Not done
9/10 (2) 9/10 (56) 5/6 (82)§
8/10 (18) 4/6 (63) §
Median CD34+ 106/kg (range) 7.91 (0.49-31.20) 6.03 (0.63-27.40) 0.09¶ (0.02-0.64) <.001
RD indicates related donor; URD, unrelated donor; CB, cord blood; CMV, cytomegalovirus; PBSC, peripheral blood stem cell; BM, bone marrow; MDS,
myelodysplastic syndrome; CML, chronic myeloid leukemia; TBI, total-body irradiation; GVHD, graft-versus-host disease; CNI, calcineurin inhibitor;
HLA, human leukocyte antigen.
*Non-Hodgkin lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, and multiple myeloma.
†1320-1375 cGy [12,30] and 400 cGy [10] were the most common TBI doses used for high-dose and reduced-intensity myeloablative conditioning.
‡High-dose myeloablative conditioning consisted of high-dose busulfan/melphalan [31] or clofarabine/melphalan/thiotepa. Reduced-intensity myeloabla-
tive conditioning was usually busulfan/melphalan/fludarabine [32] or melphalan/fludarabine.
§Represents donor-recipient HLA match of 150 units.
¶Represents dose/unit of 150 units.
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day 100), and cGVHD were defined according to the
National Institutes of Health consensus criteria [16].
Late aGVHD and cGVHD were analyzed together
in patientswho survived for at least 100 dayswith donor
engraftment. Relapse was defined as recurrence or pro-
gression of disease over pretransplant baseline, whereas
transplant-related mortality (TRM) was defined as
death from any cause in continued remission. Overall
survival (OS) and PFS were defined according to stan-
dard criteria. The primary cause of death was defined
according to the algorithm of Copelan et al. [17].Statistical Analysis
Data on patient characteristics and transplant-
related outcomes were obtained from the prospectively
maintained MSKCC BM Transplant database, withadditional chart review as required. Outcomes were
analyzed as of December 31, 2009. Survivors had ame-
dian follow-up of 22months (range: 6-52), and this was
similar between HSC sources. Patient and graft char-
acteristics among the 3 HSC sources were compared
using the Fisher’s exact test for categoric variables
and the Wilcoxon rank sum test for continuous vari-
ables. The incidence of neutrophil and platelet en-
graftment, aGVHD, late aGVHD/cGVHD, TRM,
and relapse were computed using the cumulative inci-
dence function, and Gray’s test was used to assess the
differences between HSC sources. OS and PFS were
calculated using Kaplan-Meier methodology for each
HSC source and were compared using the log-rank
test. Endpoints at specific posttransplant time points
were compared using the Wald test. Multivariate
Cox regression analysis was performed to ascertain
whether HSC source was a significant predictor of
Biol Blood Marrow Transplant 17:1316-1326, 2011 1319Survival after Cord Blood TransplantationPFS controlling for age, disease risk, and method of
GVHD prophylaxis. As 10/10HLA-matched and mis-
matched URD-T recipients had similar outcomes
(with the exception of a higher incidence of aGVHD
in the recipients of mismatched unmodified URD-
T), all URD-T recipients were combined for the pur-
poses of comparison to RD-T and CB-T. Analyses
were completed using SAS 9.2 software (SAS Institute
Inc., Cary, NC) and R version 2.9.2.RESULTS
Characteristics of Patients and Grafts
One hundred eight RD-T, 184 URD-T, and 75
CB-T consecutive patients fulfilled eligibility criteria.
Patient and graft characteristics are summarized in
Table 1. All 3 groups had similar age, gender, weight,
recipient cytomegalovirus (CMV) seropositivity, and
disease risk. A similar percentage had acute leukemia,
with a similar proportion of AML and ALL among
the 3 HSC sources. A higher percentage of RD-T
and URD-T recipients had MDS, and a higher per-
centage of CB-T recipients had lymphoma. Conse-
quently, a higher percentage of CB-T recipients had
had a prior autologous transplant. The majority of
the patients in the 3 groups receivedmyeloablative con-
ditioning. Approximately two-thirds of RD-T and
URD-T grafts were T cell depleted, whereas all CB
grafts consisted of double units and were unmodified.
Nearly all (98%) RD-T recipients received grafts
that were 10/10 HLA-allele matched, and the majority
(60%) of URD grafts were 10/10HLA-allele matched.
CB units were markedly HLAmismatched at high res-
olution. Although the donor-recipient HLA-match of
CB units was 6/6 (n5 5), 5/6 (n5 82), or 4/6 (n5 63)
at HLA-A and -B antigens and -DRB1 alleles, units
were only a median of 6/10 HLA-allele matched
(range: 2-9/10) to the patient. CB-T recipients also
received more than a log less cells compared to non-
CB-T recipients.Neutrophil and Platelet Engraftment
The incidences of engraftment after transplanta-
tion of the 3 HSC sources are compared in Table 2.
Recipients of myeloablative CB-T had a slower
neutrophil recovery than myeloablative RD-T or
URD-T recipients (P \ .001). However, there was
no difference between the 3 transplant groups in the
speed of neutrophil recovery after nonmyeloablative
conditioning. The 93% (95% confidence interval
[CI]: 87-99) cumulative incidence of sustained neutro-
phil engraftment after CB-T was accounted for by 1
unit in nearly all patients, and was lower than the other
HSC sources. Five CB-T recipients had graft failure.
Four received myeloablative conditioning and hadprimary (n5 3) or early secondary (n5 1) graft failure.
In these patients, early-onset multiorgan failure on
days 7 and 11 (n 5 2), early CMV infection (n 5 1),
and human herpesvirus 6 viremia [18] (n 5 1) may
have contributed to the failure of engraftment. One
additional nonmyeloablative CB-T recipient had pri-
mary graft failure with autologous recovery.
By contrast, only 1 graft failure was seen in a RD-T
recipient. This patient had secondary graft failure 4
months after a myeloablative T cell–depleted 10/10
HLA-matched RD graft, but achieved sustained donor
engraftment after a stem cell boost. None of the
unmodified URD-T recipients had graft failure. How-
ever, among recipients of URD myeloablative T cell–
depleted grafts, 10 (8 8-9/10 HLA-matched, and 2 10/
10 HLA-matched) had secondary graft failure. Six of
these patients were successfully treated, and 1 had
spontaneous recovery of donor hematopoiesis. Thus,
only 3 URD-T recipients had sustained failure of
donor-derived neutrophil engraftment.
The cumulative incidence of day 180 platelet en-
graftment to .50  109/L was 80% (95% CI: 71-89)
in CB-T recipients and occurred at a median of 51
days (range: 35-182) for recipients of myeloablative
conditioning and 38 days (range: 21-59) for nonmye-
loablative recipients. This incidence of recovery was
lower than both RD-T recipients (99% [95% CI: 96-
100]), and URD-T recipients (93% [95% CI: 89-97])
(P \ .001). The subset of CB-T recipients alive at
day 100, however, had a 97% (95% CI: 92-100) inci-
dence of sustained platelet engraftment by day 180.
This was lower than the 100% (95% CI: 98-100)
rate observed in RD-T recipients (P 5 .035), but sim-
ilar to the 98% (95% CI: 95-100) rate seen in URD-T
recipients (P 5 .215), alive at day 100.Acute and Late aGVHD/cGVHD
The cumulative incidence of grade II-IV aGVHD
at day 100 was 43% (95% CI: 31-54) in CB-T recipi-
ents. This was not different from that of unmodified
RD-T or unmodified URD-T recipients (P 5 .326)
(Table 2).
The cumulative incidence of late aGVHD/
cGVHD at 1 year in CB-T recipients was 28% (95%
CI: 18-38) (Table 2) and consisted predominantly of
ongoing aGVHD after day 100 or overlap syndromes.
This was similar to the 31% (95% CI: 15-47) 1-year
incidence of unmodified RD-T recipients, but lower
than the 44% (95% CI: 31-58) 1-year incidence of un-
modified URD-T recipients (P 5 .015). When com-
pared to T cell–depleted grafts, the incidence of late
aGVHD/cGVHD at 1 year in CB-T was higher than
the 12% (95%CI: 4-20) incidence of RD-T recipients,
but the difference with the 19% (95% CI: 12-27)
incidenceURD-T recipients did not reach significance
(P5 .072).
Table 2. Comparison of Engraftment, GVHD, Relapse, and Survival Endpoints after RD-T, URD-T, and CB-T: 2-Year OS and PFS
after CB-T, RD-T, and URD-TWere Similar
RD (n 5 108) URD (n 5 184) CB (n 5 75) P Value
Median time to ANC $0.5 
109/L (days)
MA: 11 (range: 8-24) MA: 11 (range: 9-29) MA: 24 (range: 12-43) MA: <.001
NMA: 11 (range: 1-18) NMA: 10 (range: 1-20) NMA: 10 (range: 7-36) NMA: .084
Sustained neutrophil engraftment 100% (95% CI: 100-100) 97% (95% CI: 95-100) 93% (95% CI: 87-99) <.001
Median time to platelet $50 
109/L (days)
MA: 17 (range: 10-90) MA: 18 (range: 11-67) MA: 51 (range: 35-182) <.001
NMA: 12 (range: 1-32) NMA: 17 (range: 1-27) NMA: 38 (range: 21-59) <.001
Day 180 platelet engraftment:
All patients
99% (95% CI: 96-100) 93% (95% CI: 89-97) 80% (95% CI: 71-89) CB-T vs RD-T 0.035




Unmodified: 27% (95%CI: 12-42) Unmodified: 39% (95% CI: 26-52) 43% (95% CI: 31-54) .326*
TCD: 8% (95% CI: 2-15) TCD: 9% (95% CI: 4-14)
1-Year late acute or chronic GVHD Unmodified: 31% (95% CI: 15-47) Unmodified: 44% (95% CI: 31-58) 28% (95% CI: 18-38) .044*
TCD: 12% (95% CI: 4-20) TCD: 19% (95% CI: 12-27) CB-T vs Unmodified
URD-T 0.015
2-Year relapse/progression Unmodified: 19% (95% CI: 6-32) Unmodified: 9% (95% CI: 0-18) 20% (95% CI: 10-29) 0.813
TCD: 19% (95% CI: 10-29) TCD: 24% (95% CI: 16-31)
Day 180 TRM 8% (95% CI: 3-14) 13% (95% CI: 8-18) 21% (95% CI: 12-31) CB-T vs RD-T 0.017
CB-T vs URD-T .123
2-Year TRM 15% (95% CI: 8-23) 27% (95% CI: 20-34) 25% (95% CI: 15-35) .183
2-Year overall survival 70% (95% CI: 61-80) 62% (95% CI: 54-70) 65% (95% CI: 55-77) .602
2-Year progression-free survival 66% (95% CI: 57-76) 55% (95% CI: 48-64) 55% (95% CI: 45-68) .573
RD indicates related donor; URD, unrelated donor; CB, cord blood; n, number; ANC, absolute neutrophil count; MA, myeloablative; NMA, nonmye-
loablative; CI, confidence interval; GVHD, graft-versus-host disease; TCD, T cell depletion; TRM, transplant-related mortality; vs, versus.
* Comparison between CB-T, unmodified RD-T, and unmodified URD-T recipients.
Figure 1. The cumulative incidence of TRM after CB-T, RD-T, and
URD-T: increased early mortality after CB-Twas compensated for by
reduced late mortality such that the 2-year TRM after CB-Twas not dif-
ferent from that of RD-T and URD-T recipients.
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The overall cumulative incidence of relapse/pro-
gression was not different between the 3 groups (P 5
.813) (Table 2). Only 1 of the 27 CB-T recipients
with a myeloid malignancy relapsed. The risk for re-
lapse or progression was higher among patients with
high-risk disease (data not shown).
Survival Endpoints
The 2-year TRM after CB-T, RD-T, and URD-T
were not different: 25% (95% CI: 15-35), 15% (95%
CI: 8-23), and 27% (95% CI: 20-34), respectively
(P 5 .183) (Table 2 and Figure 1). Notably, the early
TRM in the first 180 days after CB-T was 21%
(95% CI: 12-31). This compared to 8% (95% CI: 3-
14) after RD-T (P 5 .017), and 13% (95% CI: 8-18)
after URD-T (P 5 .123). However, this was compen-
sated for by a relatively low TRM after day 180 in CB-
T recipients.
With a median follow-up of 22 months (range: 6-
52), 65% (95% CI: 55-77) of CB-T recipients were
alive at 2 years. This OS was similar to that seen in
RD-T recipients (70% [95% CI: 61-80]), and URD-
T recipients (62% [95% CI: 54-70]) (Table 2,
Figure 2). There was also no difference in the PFS
(P 5 .573), with the 2-year PFS of 55% (95% CI:
45-68) in CB-T, 66% (95% CI: 57-76) in RD-T,
and 55% (95% CI: 48-64) in URD-T recipients as
shown in Table 2 and Figure 3.
Multivariate Cox regression analysis showed that
the HSC source was not associated with PFS (RD-T
versus CB-T hazard ratio 0.68 [95% CI: 0.39-1.20],
P 5 .185; URD-T versus CB-T hazard ratio 0.78[95% CI: 0.47-1.29], P 5 .329). The method of
GVHD prophylaxis was also not significant (unmodi-
fied versus TCD hazard ratio 0.83 [95% CI: 0.55-
1.25], P 5 .362). The only significant factors were
age at transplantation (increasing age per 5 years haz-
ard ratio 1.07 [95% CI: 1.02-1.11], P 5 .005), and
high-risk disease (high-risk versus standard-risk dis-
ease hazard ratio 2.48 [95% CI: 1.33-4.60], P 5 .004).Causes of Death
In order to better understand the causes of early
versus late mortality after CB-T, a detailed cause of
Figure 2. The Kaplan-Meier incidence of OS after CB-T, RD-T, and
URD-T: OS after CB-T was similar when compared with RD-T and
URD-T.
Figure 3. The Kaplan-Meier incidence of PFS after CB-T, RD-T, and
URD-T: 2 year PFS after CB-T was not different from that of RD-T
and URD-T recipients.
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(Table 3). Overall, the percentage of CB-T recipients
who died before day 180 posttransplantation was 25%
(19/75), compared to 14% (15/108) of RD-T and 16%
(29/184) of URD-T recipients. Organ failure was the
leading cause of early mortality in CB-T recipients
(n57/19, 37%).Organs involved included lung (n54),
liver (n 5 2), and central nervous system (n 5 1). This
was followed by early deaths because of graft failure, re-
lapse, and GVHD, with the least common primary
cause of early mortality being infection. The leading
cause of early mortality in RD-T recipients was relapse
and in URD-T recipients was GVHD.
Notably, however, the increased early mortality
after CB-T was compensated for by a decreased late
mortality after day 180, which was observed in only
7/56 (13%) of CB-T recipients alive at day 180. This
compared with 17/93 (18%) of RD-T, and 38/155
(25%) of URD-T recipients alive at day 180. The lead-
ing cause of late mortality in CB-T recipients was re-
lapse (n 5 5, 71%), with no late deaths from graft
failure, organ failure, or infection. The leading cause
of late mortality in both RD-T and URD-T recipients
was also relapse, followed by GVHD.
A comparison of the causes of death in the first 2
years after transplantation of the 3 HSC sources is
shown in Figure 4. Overall, relapse was the leading pri-
mary cause of death in each group. Further, GVHD
was as common as graft failure as a primary cause of
death after CB-T.Comparison of Transplant Outcomes after
RD-T, URD-T, and CB-T in Patients
with Acute Leukemia
The subset of 202 patients (64 RD-T, 99 URD-T,
and 39 CB-T) with acute leukemia was analyzed in or-
der to compare outcomes of a more uniform patient
group. A similar percentage of the 3 subgroups were
adults and they had similar genders, weights, and ratesof CMV seropositivity (Table 4). Nearly all patients
received myeloablative conditioning. However, CB-
T recipients had more advanced disease, with only
19 (49%) in first CR compared to 47 (73%) of RD-T
and 59 (60%) URD-T recipients (P 5 .048). Out-
comes are compared in Table 5. Rates of neutrophil
and platelet engraftment, and aGVHD were similar
to those observed in the overall analysis. There was
no difference in the incidence of late aGVHD/
cGVHD among unmodified RD-T, unmodified
URD-T, and CB-T recipients (P 5 .915).
As in the entire dataset, a relatively high mortality
in the first 180 days posttransplant in CB-T recipients
with acute leukemia was compensated by a reduced
late mortality. Most notably, the incidence of relapse
over the first 2 years posttransplant was low in CB-T
recipients at only 5% (95% CI: 0-12) (Figure 5, P 5
.072 by log-rank analysis). Statistical comparison of
the 2-year relapse incidence using the Wald test
showed this 5% incidence after CB-T was significantly
lower than that of all RD-T recipients (P5 .007), and
URD-T recipients transplanted with T cell depletion
(P 5 .008), and similar to that seen after unmodified
URD-T (P5 .686). Over the entire follow-up period,
the OS (P5 .491), and DFS (P5 .482) in patients with
acute leukemia were similar among the 3 transplant
groups by log-rank analysis.DISCUSSION
Survival after CB-T has significantly improved in
the last decade, especially in adults. Possible contribu-
tors to this success have been better patient selection,
a larger global CB inventory, the use of fludarabine-
based conditioning regimens, substitution of mycophe-
nolate mofetil immunosuppression for corticosteroids
[19,20], the introduction of double units CB grafts
Table 3. Primary Cause of Death after CB-T: A Relatively Low Incidence of Late Mortality Compensated for a Higher Early
Posttransplant Mortality
Primary COD/N/
% COD in 2 Years Early Mortality <180 days (n 5 19/75) Late Mortality >180 days (n 5 7/56)
Median (Range)
Day of Death
Relapse n 5 8, 31% Myeloablative conditioning
- ALL CR1 (high-risk cytogenetics).
- Lymphoblastic NHL PR2.
- T cell NHL CR2.
Myeloablative conditioning
- Lymphoblastic NHL CR2.
- ALL CR1 after refractory CNS disease.
- HL PR3. Short remission post-auto Tx.
- HL PR2. 3 regimens to obtain PR2.
Nonmyeloablative conditioning
- DLC NHL CR3, prior auto Tx.
239 days (range: 119-877)
Graft Failure n 5 4, 15% - ALL CR3. Early CMV pneumonia.
- ALL CR2. GF with HHV6 viremia.
- ALL CR3. Sepsis/MOF day 7 (100% donor).
- AML CR2. Cardiomyopathy pre-Tx.
Cardiac failure day 11 (100% donor).
46 days (range: 30-106)
GVHD n 5 5, 19% - AML CR2. CNI subtherapeutic.
- ALL CR1. CNI subtherapeutic.
- NHL CR2.
- AML CR1. CNI subtherapeutic.
- Transformed indolent NHL >PR3.
170 days (range: 70-445)
Organ failure (primary organ
involved) n 5 7, 27%
Myeloablative conditioning
- AML CR2. Extensive prior therapy (Liver).
- Lymphoblastic NHL PR2 (Lung).
- ALL CR2, heavily pretreated (Lung).
- AML CR1 (Liver).
- AML CR2. Lung pathology pre-Tx (Lung).
- ALL CR1. CNS RT pre-Tx (Brain).
Nonmyeloablative conditioning
- Transformed indolent NHL PR2 (Lung).
78 days (range: 30-140)
Infection n 5 2, 8% - Follicular NHL >PR3. CMV pneumonia.
- Transformed indolent NHL >PR3. HHV6
encephalitis.
72 days (range: 69-75)
COD indicates cause of death; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; NHL, non-Hodgkin lymphoma; CR, complete
remission; PR, partial remission; HL, Hodgkin lymphoma; DLC, diffuse large cell; auto, autologous; Tx, transplantation; CMV, cytomegalovirus; MOF,
multiorgan failure; VOD, veno-occlusive disease; GF, graft failure; HHV6; human herpesvirus 6; CNI, calcineurin inhibitor; GVHD, graft-versus-host
disease; FL, follicular lymphoma; CNS, central nervous system; RT, radiotherapy.
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investigating CB as an alternative HSC source and
have found CB-T extends transplant access to racial
and ethnic minorities [5], and double-unit CB-TFigure 4. Comparison of causes of death in the 2-year posttransplant accordin
primary cause of death in RD-Tand CB-Trecipients, whereas relapse and GVHaffords promising survival [10]. Thus, a comparison
of double-unit CB-T to transplantation with tradi-
tional HSC sources is both timely and appropriate. Al-
though our study is retrospective and not randomized,g to HSC source: relapse followed by organ failure was themost frequent
D were the most frequent primary causes of death in URD-Trecipients.
Table 4. Demographics and Graft Characteristics in Patients with Acute Leukemia: Although CB-T Recipients Were Younger,
a Similar Percentage Were Adults, and CB-T Recipients Had More Advanced Disease
RD (n 5 64) URD (n 5 99) CB (n 5 39) P Value
Median age (range) 46 (<1-68) 46 (1-71) 27 (<1-66) .073
n (%) age >21 years 48 (75%) 69 (70%) 25 (64%) .490
n (%) male 36 (56%) 50 (51%) 20 (51%) .749
Median weight kg (range) 73(9-122) 71 (8-109) 63 (7-102) .115
n (%) recipient CMV seropositive 31 (48%) 45 (45%) 22 (56%) .536
n (%) prior autologous transplant 1 (2%) 3 (3%) 2 (5%) .575
n (%) conditioning regimen
Myeloablative 63 (98%) 99 (100%) 39 (100%) Not done
Nonmyeloablative 1 (2%) — —
n (%) remission status
CR1 47 (73%) 59 (60%) 19 (49%) .048
CR2 16 (25%) 31 (31%) 15 (38%)
CR3 1 (2%) 9 (9%) 5 (13%)
n (%) disease risk
Standard 7 (11%) 4 (4%) 1 (3%) .172
High 57 (89%) 95 (96%) 38 (97%)
n (%) myeloablative conditioning
(High dose and reduced intensity)
TBI-based* 39 (61%) 48 (48%) 35 (90%) Not done
Chemotherapy-based† 24 (38%) 51 (52%) 4 (10%)
n (%) Nonmyeloablative conditioning
TBI-based (200 cGy) 1 (2%) — —
n (%) GVHD prophylaxis —
T cell depletion 52 (81%) 88 (89%)
CNI ± other 12 (19%) 11 (11%) 39 (100%) Not done
Median donor-recipient HLA-A, -B, -C,
-DRB1, -DQ match (range)
10/10 (9-10/10) 10/10 (8-10/10) 5/10 (2-8/10) better
matched unit
<.001








Median CD34+ 106/kg (range) 7.79 (0.49-31.20) 5.99 (0.68-22.20) 0.09§ (0.08-0.64) <.001
RD indicates related donor; URD, unrelated donor; CB, cord blood; CMV, cytomegalovirus; TBI, total-body irradiation; GVHD, graft-versus-host
disease; CNI, calcineurin inhibitor; HLA, human leukocyte antigen.
*1320-1375 cGy [12,30] and 400 cGy [10] were the most common TBI doses used for high-dose and reduced-intensity myeloablative conditioning.
†High-dose myeloablative conditioning consisted of high-dose busulfan/melphalan [31] or clofarabine/melphalan/thiotepa. Reduced-intensity myeloabla-
tive conditioning was usually busulfan/melphalan/fludarabine [32] or melphalan/fludarabine.
‡ Represents donor-recipient HLA match of 78 units.
§Represents dose/unit of 78 units.
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RD andURD transplantation that were either unmod-
ified or T cell depleted, and performed over the same
time period in a single institution with similar support-
ive care measures.
We found a 93% incidence of sustained donor en-
graftment after CB-T. This is similar to prior series of
double-unit CB-T [22,23]. However, this engraftment
incidence was lower than that of RD-T and URD-T
recipients. Two of 5 CB-T recipients classified as hav-
ing graft failure as their primary cause of death had
multiorgan failure within the first 11 days posttrans-
plant. This likely contributed to their poor count re-
covery, given both patients were 100% donor in their
day 21 bone marrow. Viral infections with CMV and
human herpesvirus 6 may have contributed to 2 addi-
tional graft failures in CB-T recipients. A larger CB in-
ventory to enable transplantation of units with higher
TNC dose and better HLA-match will facilitate im-
proved engraftment [24]. More effective viral prophy-
laxis could also be beneficial. We also found a high
incidence of secondary graft failure in TCD URD-Trecipients. However, 7/10 of these patients achieved
sustained donor engraftment after stem cell boost or
spontaneous recovery, contributing to a higher rate
of sustained donor engraftment after URD-T. Platelet
recovery after CB-T was also inferior to other HSC
sources, although it was identical toURD-T recipients
in patients alive at day 100. This reflects the vulnerabil-
ity of platelet recovery inCB-T recipients who are crit-
ically ill early posttransplant, and demonstrates that
platelet recovery in long-term survivors of CB-T is
nearly always adequate.
CB-T recipients had a similar incidence of
aGVHD as seen after the transplantation of unmodi-
fied grafts from related or unrelated donors. In addi-
tion, their incidence of late aGVHD/cGVHD was
similar to unmodified RD-T and lower than unmodi-
fiedURD-T recipients. However, GVHDwas the pri-
mary cause of death in 5 CB-T recipients. By contrast,
despite the prolonged neutropenia after CB-T, infec-
tion was the primary cause of death in only 2 patients.
Therefore, GVHD is at least as much of a problem as
graft failure, and a greater threat than infection as the
Table 5. Comparison of TransplantOutcomes after RD-T, URD-T, andCB-T in Patients with Acute Leukemia: 2-Year Disease-Free
Survival after CB-T, RD-T, and URD-TWere Similar
RD (n 5 64) URD (n 5 99) CB (n 5 39) P Value
Median time to ANC 109/L (days) 11 days (range: 8-24) 11 days (range: 9-18) 23 days (range: 12-43) <.001
Sustained neutrophil engraftment 100% (95% CI: 97-100) 97% (95% CI: 93-100) 90% (95% CI: 79-100) <.001
Grade II-IV acute GVHD at day 100 Unmodified: 17% (95% CI: 0-39)
TCD: 8% (95% CI: 0-15)
Unmodified: 45% (95% CI: 14-77)
TCD: 10% (95% CI: 4-17)
41% (95% CI: 25-57) .324*
Late acute or chronic GVHD at 1 year Unmodified: 30% (95% CI: 0-62)
TCD: 6% (95% CI: 0-12)
Unmodified: 18% (95% CI: 0-42)
TCD: 22% (95% CI: 13-31)
26% (95% CI: 12-40) .915*
TRM at 2 years 12% (95% CI: 3-21) 28% (95% CI: 18-37) 32% (95% CI: 16-47) .035
Relapse at 2 years Unmodified: 25% (95% CI: 0-51)
TCD: 22% (95% CI: 10-34)
Unmodified: 9% (95% CI: 0-27)
TCD: 20% (95% CI: 12-29)
5% (95% CI: 0-12) .072
Overall survival at 2 years 68% (95% CI: 57-82) 58% (95% CI: 48-69) 63% (95% CI: 49-81) .491
Disease-free survival at 2 years 65% (95% CI: 54-79) 53% (95% CI: 43-65) 63% (95% CI: 49-81) .482
RD, related donor; URD, unrelated donor; CB, cord blood; ANC, absolute neutrophil count; CI, confidence interval; GVHD, graft-versus-host disease;
TCD, T cell depletion; TRM, transplant-related mortality.
* Comparison between CB-T, unmodified RD-T, and unmodified URD-T recipients.
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tients who died of GVHD had subtherapeutic CNI
levels early posttransplant (data not shown). Thera-
peutic CNI levels are likely critical in the prevention
of GVHD after CB-T, as has been reported in RD
and URD transplantation [25]. Although we are now
investigating increased dosing of mycophenolate mo-
fetil to ensure therapeutic blood levels [26], additional
strategies are needed, especially for those who are un-
able to tolerate therapeutic levels of CNI because of
renal impairment or other toxicities. A larger inven-
tory of CB units will be helpful, given the critical influ-
ence of HLA-match upon aGVHD risk after
single-unit CB-T [24], which will likely also apply to
the engrafting unit in double-unit CB-T recipients.
Overall, the incidence of relapse was similar among
the groups. Interestingly, only 1 of 27 CB-T recipients
with myeloid malignancies relapsed, and the 2-year in-
cidence of relapse in CB-T recipients with acute leuke-
mia was only 5%. Our observation of a reduced
incidence of relapse in CB-T recipients with acuteFigure 5. Comparison of relapse after CB-T, RD-T, and URD-T in pa-
tients with acute leukemia transplanted in remission: CB-T recipients
had a low risk of relapse.leukemia (P 5 .072) is consistent with the findings of
Brunstein et al. [27], who found myeloablative double
unit CB-T recipients with acute leukemia or CML had
a reduced relapse incidence compared with related and
unrelated donor transplant recipients. In our study, al-
though the difference between relapse risk in CB-T re-
cipients with myeloid and lymphoid malignancies may
have been contributed to by greater disease risk in the
latter group, these observations support a potent graft-
versus-leukemia effect after double-unit CB-T as sug-
gested by Verneris et al. [28]. We hypothesize this
could be related to the immune-mediated graft-
versus-graft interactions between the 2 CB units [29],
which could impact minimal residual disease. More-
over, the apparent robust protection against relapse
in acute leukemia, combined with an increased
risk of organ failure after high-dose conditioning
(Table 3), suggests investigation of reduced-intensity
double-unit CB-T may be appropriate in leukemic
patients in remission.
Notably, a higher incidence of TRM was seen in
CB-T recipients in the first 6 months posttransplant
compared with RD-T recipients. This was most com-
monly because of early posttransplant organ failure.
Although deaths because of veno-occlusive disease
and central nervous system toxicity were not attribut-
able to prolonged count recovery (Table 3), a contribu-
tion from prolonged neutropenia must be considered
in pulmonary deaths. Methods to speed neutrophil re-
covery and possibly reduced-intensity conditioning
(RIC) will likely be required to ameliorate this toxicity.
Notably, however, the increased early mortality risk in
CB-T recipients was compensated for by a reduced
late mortality risk. Therefore, CB-T recipients that
survive the first 6 months posttransplant are unlikely
to die of transplant-related causes. Further, CB-T re-
cipients who receive transplants in remission have a rel-
atively low risk of relapse. This relatively reduced risk
of late mortality after CB-T contributed to a similar 2-
year OS and PFS as observed in RD-T and URD-T
Biol Blood Marrow Transplant 17:1316-1326, 2011 1325Survival after Cord Blood Transplantationrecipients. Further, in multivariate analysis, the HSC
source had no impact on PFS, with the only significant
factors being high-risk disease and increasing age.
The similar PFS after CB-T compared to the
transplantation of the traditional HSC sources is re-
markable given the relatively low cell dose and degree
of HLA disparity of CB grafts. Our study, like that of
Brunstein et al. [27], who reported comparable 5-year
leukemia-free survival after double-unit CB-T and re-
lated and unrelated donor transplantation, supports
the use of double-unit CB grafts for the transplanta-
tion of children and adults. Our results are of particular
significance given, unlike URD-T, .50% of our CB-
T recipients have non-European ancestry [5]. Thus,
CB-T can extend transplant access to racial and ethnic
minorities, and potentially achieve similar PFS. We
acknowledge that themain limitation of this retrospec-
tive study is the heterogeneity of the patient popula-
tion. CB-T recipients were, for example, a decade
younger than RD-T or URD-T recipients. Although
it is encouraging that, in the subset analysis of acute
leukemia patients, we found similar 2-year DFS after
transplantation of the 3 HSC sources, these results
must be confirmed with larger studies of uniform pa-
tient populations. Further, our results may have been
contributed to by a center effect [24], given we have
a specific interest in CB-T, and other centers without
CB-T experience may not be able to replicate these
findings. Nonetheless, the outcomes of our study sup-
port wider adoption of CB-T. We propose centers
consider double-unit CB-T as a potential treatment al-
ternative in all patients with high-risk hematologicma-
lignancies who are allograft candidates and do not have
any suitable related or unrelated donors, or require an
urgent transplant (within 8-10 weeks of URD search
initiation). Further, as center experience with CB-T
increases, a randomized study between CB-T and
URD-T may be appropriate in the future.ACKNOWLEDGMENTS
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